Tumori Journal

Papers
(The TQCC of Tumori Journal is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Exploring new frontiers: Outcomes and feasibility of a third radiotherapy course in recurrent prostate cancer57
A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval43
Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer17
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide13
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis12
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study11
Fertility and abortion: A population-based comparison between women with cancer and those in childbearing age10
Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort9
Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial8
Blooming in the rain8
Chemo-surgical approach in vulvar leiomyosarcoma: A case report8
Is motherhood still possible after pelvic carbon ion radiotherapy? A promising combined fertility-preservation approach8
Oral vinorelbine in young patients with desmoid-type fibromatosis7
The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumors7
Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer7
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients7
Prognostic value of Aurora B expression in cancer patients: A meta-analysis6
Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma6
Ongoing discussion: Is prophylactic central neck dissection necessary in c T 1a-b,2 N 6
Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients6
Humanistic nursing combined with Neuman’s nursing in the application for oncology patients6
Emerging therapeutic strategies in Lynch syndrome-associated colorectal cancer and the role of MMR testing6
Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal6
Expression of concern6
Enhanced patient journey associated with improved overall survival in colon cancer patients: A study by the Ligurian Oncology Network6
Advances in spatial multi-omics in tumors5
Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL5
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients5
Time trends of cancer incidence in young adults (20-49 years) in Italy. A population - based study, 2008-20175
Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes5
Quality assurance for cancer patient safety: Clinical assessment for precise angles in linac during radiation therapy4
Hippocampal region avoidance in whole brain radiotherapy in brain metastases: For all or for some? A real-world feasibility report4
KRAS inhibitors in drug resistance and potential for combination therapy4
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology4
Personalized treatment using predictive biomarkers in solid organ malignancies: A review4
Effect of anti-inflammatory molecules from food on organoids derived from adenomatous polyps of FAP subjects4
Periprosthetic effusions surrounding breast expander: a flow cytometric, immunohistochemical and molecular characterization4
Ethics in the evaluation of the quality of scientific research: An AIOM-TJ roundtable4
Secular trends in incidence and mortality of non-Hodgkin’s lymphoma in China, 1990–2019, and predictions to 2030: Outlook for the future burden of disease4
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes4
15th BGICC Abstract Book 20234
Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC4
Outcomes of chemotherapy/chemoradiation vs. R2 surgical debulking vs. palliative care in nonresectable locally recurrent rectal cancer4
ESCO1 as a novel predictive biomarker and potential therapeutic target in renal cell carcinoma4
Corrigendum to: AIRO Breast Cancer Group Best Clinical Practice 2022 Update4
Self-perceived attitudes of Italian oncology nurses towards clinical trial involvement: A cohort observational study4
Current practices of follow-up programs for childhood cancer survivors in Italy4
Nutritional status as a risk factor for adverse events associated with L-Asparaginase in children with acute lymphoblastic leukemia4
Survey among childhood cancer survivors about their preferences on functionalities of a to-be-developed Survivorship Passport Mobile App4
MLH1 promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of MLH1 gene?3
Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report3
End-of-Life transfusion support at hospice and pediatric oncology unit: Bridging the gap between benefits and therapeutic alliance3
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making3
Advancing biomarker development for diagnostics and therapeutics using solid tumour cancer stem cell models3
Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation3
Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?3
AIOM Abstract3
Italian translation, cultural adaptation and pilot testing of Psychosocial Assessment Tool (PAT 3.1) in pediatric cancer3
A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy3
Generative AI and medical oncologists: Be curious, but cautious!3
Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience3
Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis3
CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice3
I was only sixteen3
0.089088201522827